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ABSTRACT: GPR35 is a class A, rhodopsin-like G protein-coupled
receptor (GPCR) first identified more than 20 years ago. In the intervening
period, identification of strong expression in the lower intestine and colon,
in a variety of immune cells including monocytes and a variety of dendritic
cells, and in dorsal root ganglia has suggested potential therapeutic
opportunities in targeting this receptor in a range of conditions. GPR35 is,
however, unusual in a variety of ways that challenge routes to translation.
These include the following: (i) Although a substantial range and diversity
of endogenous ligands have been suggested as agonist partners for this
receptor, it officially remains defined as an “orphan” GPCR. (ii) Humans
express two distinct protein isoform sequences, while rodents express only
a single form. (iii) The pharmacologies of the human and rodent
orthologues of GPR35 are very distinct, with variation between rat and mouse GPR35 being as marked as that between either of
these species and the human forms. Herein we provide perspectives on each of the topics above as well as suggesting ways to
overcome the challenges currently hindering potential translation. These include a better understanding of the extent and molecular
basis for species selective GPR35 pharmacology and the production of novel mouse models in which both “on-target” and “off-
target” effects of presumptive GPR35 ligands can be better defined, as well as a clear understanding of the human isoform expression
profile and its significance at both tissue and individual cell levels.
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1. GPR35 ISOFORMS AND ORTHOLOGUES
The human GPR35 gene can be transcribed and translated into
three variants.1 Variants 2 and 3 both encode the same longer
isoform, GPR35b, which differs from GPR35a by an additional
N-terminal extension of 31 amino acids, resulting in a longer
extracellular domain but subsequent equivalence in sequence
(Figure 1). Orthologues of GPR35 are found also in both
mouse and rat. However, three transcript variants in mouse
and one in rat each encode a single GPR35 species which have
73 and 72% identity with human GPR35a.2 Although
distribution of mRNA expression of GPR35a and GPR35b in
human tissues has been established,3 potential distinctive
functions of GPR35a and GPR35b are unknown as they
display highly similar pharmacology4−6 and, where examined,
signaling mechanisms. The extracellular domain of GPR35b
does not appear to result in differential targeting as the
isoforms localize to similar subcellular compartments when
expressed in human HeLa cells and in rat neurons.4 Sequence
comparisons highlight the potential of GPR35b to form an
additional extracellular disulfide interaction compared to
GPR35a (Figure 1), but this, or its consequences, has yet to
be examined directly. It has been suggested that GPR35b may
be associated with carcinogenesis due to detection of
expression in gastric and colon cancer tissues.1,7 However,
GPR35b appears to display lower agonist response efficacy
than GPR35a.4,5,8
Although little explored, orthologues of GPR35 exist in a
wide range of species (Figure 2). For example, Xenopus
tropicalis (amphibian) GPR35 shares ∼33% identity with
human GPR35a, and although GPR35-like genes are predicted
in fish, the similarity to hGPR35 is low. Although the
pharmacology of GPR35 is generally quite distinct between
human and rat GPR35 (Table 1), given that both lodoxamide
and bufrolin are potent agonists at both these orthologues5 and
both are symmetric diacids (Table 1), researchers then9 and,
more extensively,5 explored the contribution of various
positively charged residues in these orthologues to attempt
to define the agonist binding pocket and whether variation in
such residues might help explain species selectivity of other
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ligands. Such mutagenesis and species residue swap (human to
rat) studies included R6.58Q (R240Q), R7.32S (R255S), and
L4.62 (R4.62). Interestingly, in hGPR35a the L4.62R
alteration increased potency for the agonist zaprinast, as is
the case for the full-length rat receptor compared to human
(Table 1). However, in other species residue 4.62 is quite
variable (Figure 2). It is phenylalanine in all other apes, old
world monkeys, Artiodactyla (even-toed ungulates), Cetacea
(whales and dolphins), and most Carnivora (carnivore
placental mammals), while in rodents it is almost always a
positively charged residue, usually arginine though sometimes
histidine. Residue 6.58 is positively charged in most species
except for rodents where it is predominantly glutamine.
Residue 164 is serine or glycine/alanine in most mammals,
except primates and nonmuridae rodents. The rat orthologue
lacks positive charges at residue 161 (h164) and positions 6.58
and 7.32, all of which sit in the upper portion of the predicted
binding pocket. As the more deeply located 4.62 is positively
charged in this orthologue, it is possible that ligands sit further
down in the pocket of the rat receptor. However, in the
continuing absence of direct structural details, the insights
from these studies were not definitive in defining the basis of
species ligand selectivity.
2. PHARMACOLOGY OF GPR35
2.1. Potential Endogenous Activators of GPR35. As an
orphan GPCR, the nature of the true endogenous activator(s)
of GPR35 remains undefined. This, however, does not reflect a
lack of suggestions, although these have been complicated by
issues of species selectivity, whether concentrations of
suggested ligands might be sufficient to activate the receptor
in situ and the potential signaling mechanisms engaged by the
receptor. GPR35 was nominally deorphanized when it was
shown that the tryptophan metabolite kynurenic acid could
activate human, rat, and mouse GPR35 at micromolar
concentrations.3 While these initial studies coexpressed a
panoply of promiscuous and chimeric G proteins to help to
overcome a lack of knowledge on potential selectivity of G
protein coupling,3 researchers were able to demonstrate
pertussis toxin-sensitive binding of [35S]GTPγS in response
to kynurenic acid in CHO cells transfected to express human
GPR35a. This is diagnostic of activation of Gi-family G
proteins, but the contribution and roles of Gi compared to G13
activation by GPR35 in various cells and tissues has been a
significant point of variability between studies (see later).
While it is certainly possible that kynurenic acid is indeed an
endogenous activator of GPR35 in some circumstances and,
indeed, in certain species where potency at the receptor is
relatively high, it may not act across species in an equivalent
fashion. For example, kynurenic acid is at least 40- to 100-fold
less potent at human than rat GPR35,10 and certain studies
have indicated this ligand to be almost inactive at human
GPR35, even at very high concentrations.11 This led to a
suggestion that 2-acyl lysophosphatidic acids could be
potential endogenous agonists,11 but this has not been
replicated. The most recent and indeed interesting report of
a potential endogenous agonist suggested the chemokine
CXCL17 fulfilling this role.12 Although CXCL17 was reported
to be potent and an interesting sequence alignment was used
to suggest particular relatedness of GPR35 to the atypical
chemokine receptor ACKR3 (previously designated CXCR7),
Maravillas-Montero and colleagues12 were premature in
suggesting GPR35 be renamed CXCR8 (CXC chemokine
receptor 8). A number of subsequent publications, and also
personal communications from other teams, have failed to
support the CXCL17−GPR35 pairing.13,14 Despite this, a
small number of studies have subsequently used CXCL17 in
animal models to attempt to define roles for GPR35. However,
Figure 1. Alternative splicing of the human GPR35 gene generates two isoforms, GPR35a and GPR35b. (a) The human GPR35 gene is located at
chromosome 2q.37.3. Both GPR35a and GPR35b mRNA contain exon 7, whereas GPR35b mRNA also contains exon 5. (b) This results in
GPR35b having an N-terminal extension of 31 amino acids containing a cysteine residue (marked with a red *) which may be able to form a
disulfide bond.
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for example, as kynurenic acid and zaprinast (see below)
reduced rather than mimicked the effect of CXCL17 in
neuropathic pain in mice,15 these results are not consistent
with CXCL17 acting via GPR35. Other endogenously
produced or potentially produced molecules including 5,6-
dihydroxyindole-2-carboxylic acid, reverse T3 (3,3,5-triiodo-
thyronine), and cyclic guanosine 3′-5′ monophosphate
(cGMP) have also been reported to display modest potency
at GPR35 in scattered and yet to be confirmed reports.16,17
2.2. Synthetic Agonists of GPR35. Significant effort has
been expended to identify tool compounds with which to
explore the biology of GPR35. Although better known as a
blocker of cGMP phosphodiesterases, zaprinast has remained
one of the most widely used activators of GPR35, and in many
cases has been used as a reference by which to compare
potency and efficacy of other ligands. This reflects the fact that
despite at best moderate potency and unlike many other
compounds the potency of zaprinast is relatively similar at
human, rat, and mouse orthologues.18 The general use of
human GPR35a expressed in heterologous cells for most
screening assays9,19,20 or the use of HT-29 human colorectal
adenocarcinoma cells that express the receptor endogenously
in label-free screens21,22 means that many of the most potent
reported synthetic agonists either have not been assessed at
rodent orthologues or show substantially lower potency at
either or both rat and mouse GPR35. This is true of 4-{(Z)-
[(2Z)-2-(2-fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]
methyl} benzoic acid (“compound 1” in ref 19) and the 8-
benzamidochromen-4-one-2-carboxylic acids described by
Muller and colleagues20 (Table 1), which implies that the
radiolabel 6-bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-
4H-chromene-2-carboxylic acid ([(3)H]PSB-13253) from
this series23 is unlikely to be of use in studies on rodent
orthologues of GPR35. Even between rat and mouse GPR35
there can be substantial variation in the potency of agonists.
For example, the mast cell stabilizer lodoxamide, which is
administered topically for the treatment of allergic keratocon-
junctivitis, is a potent agonist of human GPR35 and is
essentially equipotent at rat GPR35.5 However, it has greater
than 100-fold lower potency at mouse GPR35.24 Although
Kim et al.25 used lodoxamide to assess a potential role for
GPR35 in a mouse model of hepatic fibrosis, they specifically
noted the low potency of this compound at mouse GPR35,
which would seem to negate its use. Although Kim et al.25
claim that Mackenzie et al.5 reported a high potency of
lodoxamide at mouse GPR35, this is incorrect. Mackenzie et al.
did not examine mouse GPR35 in this study,5 but rather, as
noted above, the rat orthologue. In addition, Kim et al.25
reported that the effects of lodoxamide in mouse were
prevented by treatment with 1-(2,4-difluorophenyl)-5-[[2-
Figure 2. GPR35 orthologues are present in a wide range of species. GPR35 orthologues from the indicated species are aligned. Start number
indicates trimmed N-terminal extension to correspond to hGPR35a. Residues from hGPR35a noted in the text are marked as follows: spade,
L1534.62; three-leaved clover, R164; heart, R2406.58; diamond, R2557.32; ▼, T1083.44; ▲, S294. The solid black line indicates the predicted
transmembrane domains for hGPR35 (https://gpcrdb.org).
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[[(1,1-dimethylehyl)amino]thioxomethyl]hydrazinylidene]-
methyl]-1H-pyrazole-4-carboxylic acid methyl ester
(CID2745687) which (see later) is a high-affinity antagonist
of human GPR35 but lacks any significant affinity at the mouse
orthologue.26,27 While potential “off-target” effects of many
poorly studied synthetic ligands should be anticipated,
particularly in vivo, in this example a potentially “off-target”
effect of a compound possessing in vitro GPR35 agonist activity
was blocked by what must also be an “off-target” effect of a
reported (human) GPR35 antagonist. There is no obvious
reason either that lodoxamide should be an agonist or that
CID2745687 is an antagonist of a protein other than GPR35,
so the observations of Kim et al.25 are difficult to explain at a
molecular level. This provides a clear illustration that careful
pharmacological profiling of ligands at appropriate species
orthologues of a poorly characterized receptor such as GPR35
is required to allow validation of potential therapeutic
opportunities. Serendipity can be a useful ally in efforts to
identify agonists with high potency at GPR35 orthologues
beyond human: For example, amlexanox (Table 1) was
identified initially in a screen as a low-potency activator of
human GPR35,5 but subsequent studies showed it to have
substantially higher potency at rat GPR35.5 However, more
direct efforts to identify potent agonists at preclinical
orthologues of GPR35 could potentially involve direct
screening of compound libraries against a series of receptor
Table 1. GPR35 Ligands and their species Selectivitya
aPotency variation between human (h), rat (r), and mouse (m) orthologues is shown for a number of compounds with activity at GPR35. Where a
species is not shown, the relative activity has either not been reported or is very low. For the antagonists, affinity at human is markedly greater than
that for either mouse or rat.
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orthologues if the aim is then to assess receptor function in
suitable animal models of disease.
2.3. Assays Measuring Activation of GPR35. Most
studies designed to identify ligands with agonist potency at
GPR35 have employed assays that report recruitment of an
arrestin to the agonist-occupied human receptor.6,19,20 There
are many benefits in using assays based on arrestin recruitment,
not the least of which is the ease of employing these in a high-
throughput format and because GPR35 provides a particularly
robust signal in such assays. However, leaving aside the topic of
whether arrestin “recruitment” equates to “signaling”,28 it has
been challenging to develop assays suitable for high-
throughput screening of GPR35 that report G protein
activation. This may reflect that where Gi-mediated links of
GPR35 have been recorded the assays have focused on either
the binding of [35S]GTPγS1 or downstream end points where
the signal window is small, e.g., phosphorylation of the
extracellular signal regulated kinases 1 and 2,6 or for other G
protein-mediated but hard-to-automate end points that reflect
activation of Rho-kinases. This likely reflects that quantitative
comparison between different G proteins indicates that GPR35
couples most effectively with G13,
27 and until recently, assays
that record this interaction have not been compatible with
screening. However, by using a bioluminescence resonance
energy transfer (BRET)-based sensor in which human GPR35a
is linked to the C-terminal 27 amino acids of various G protein
α subunits, not only was the selectivity of the receptor for G13
confirmed but also equivalence was shown in rank-order of
potency of various agonists with those recorded in GPR35a-
arrestin interaction assays.27 Such sensors have been developed
for both human GPR35a and GPR35b8 as well as mouse
GPR3527 and should allow screening for both isoform selective
activators and potentially ligands with high potency at specified
species orthologues. In support of the conclusion that GPR35
couples selectively with G13, expression of human GPR35a in
HEK293 cells gene-edited to lack expression of different G
protein subsets showed a requirement for G12/G13 to allow
GPR35 agonists to promote shedding of an alkaline
phosphatase fusion protein of TGF-α.27 An entirely different
approach to the identification of activators of GPR35 has been
to combine the use of human HT-29 adenocarcinoma cells
that express GPR35 endogenously with a label-free assay
system that measures alterations in “dynamic mass redis-
tribution” over time.16,21 This has the distinct advantage of
assessing activation of GPR35 at endogenous levels of
expression but does require specialized equipment, and to
date, this has only been reported for human GPR35.
2.4. Antagonists of GPR35. Although antagonist
compounds are vital for characterization of GPCRs, identi-
fication and use of such tools has been fraught with challenges
for GPR35. The only well-characterized GPR35 antagonist is
methyl-5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-
(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687).6
This compound was originally shown to block effects of both
of the agonists pamoic acid and zaprinast in cells expressing
either human GPR35a or GPR35b, with Ki estimated in the
region 10−20 nM, and to potentially function in a competitive
manner (a single concentration of CID2745687 was shown to
shift the concentration−response curve for pamoic acid in an
apparently surmountable manner).6 An interesting aside in
these studies was that CID2745687 was also noted to block
effects of pamoic acid and zaprinast at mouse GPR35.6 By
contrast, Jenkins et al.26 subsequently reported that
CID2745687 was ineffective at both mouse and rat GPR35,
while confirming its ability to block effects of both zaprinast
and pamoic acid at human GPR35a. However, while more
extensive pharmacological analysis was consistent with
CID2745687 acting in a competitive manner with both
zaprinast and cromolyn disodium at this isoform with
estimated pA2 7.7−7.8, it functioned instead as a non-
competitive blocker of pamoic acid.26 Subsequent studies
using the GPR35-Gα13 BRET sensors described above have
confirmed the inability of CID2745687 to block the function
of zaprinast at mouse GPR35, but they also showed that it does
so at human GPR35a.27 As there are no atomic level structures
of any isoform or orthologue of GPR35 available to date,
neither the basis of high-affinity binding of CID2745687 to
human isoforms of GPR35 nor its observed lack of affinity at
mouse GPR35 currently have structural underpinning. More-
over, no cell-based in vitro studies since Zhao et al.6 have
provided evidence for CID2745687 being able to effectively
antagonize mouse or rat GPR35. Despite this, CID2745687
has been reported to prevent kynurenic acid mediated
inhibition of forskolin-induced cAMP production in cultured
mouse astrocytes29 and to prevent wound repair induced by a
GPR35 agonist in young adult mouse colon epithelium cells.30
Importantly, in a number of cases, associated siRNA-mediated
knockdown studies have been performed to support the
contribution of GPR35 to such end points. Furthermore, a
compound described as CID2745678 (but likely also
CID2745687 where the last two numbers have been
incorrectly inverted) was recently indicated to limit anoxia-
induced mitochondrial injury and apoptotic cell death in
neonatal murine ventricular myocytes.31 As anticipated from
the species selective pharmacology of CID2745687 defined
above, this ligand does effectively block human vascular
smooth muscle cell migration in response to either pamoic acid
or zaprinast.32 There is clearly an ongoing disconnect between
the underpinning pharmacological studies in transfected cells
and the use of this compound in some physiological
preparations that is hard to understand because the in vitro
data indicate clearly that CID2745687 should not function in
rodent tissues, at least not in a GPR35-dependent manner.
A second described GPR35 antagonist 2-hydroxy-4-[4-(5Z)-
5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanyli-
dene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid (ML-
145, CID2286812)33 also has high affinity for human
GPR3526 but is little used in practice. It also lacks appreciable
affinity for the mouse and rat orthologues,26 and as a
compound with many chemical liabilities it is useful, if at all,
only for in vitro studies.32 A single publication34 reports the use
of the compound ML-194 (1-(2,4-difluorophenyl)-5-[[2-
[[(1,1-dimethylehyl)amino]thioxomethyl]hydrazinylidene]-
methyl]-1H-pyrazole-4-carboxylic acid methyl ester) as a
potential GPR35 antagonist, but since its initial description
in a screen for GPR35 antagonists,35 it has hardly been used
and nothing is known about its activity across species.
3. POTENTIAL THERAPEUTIC OPPORTUNITIES
Although sodium cromoglycate (as RVT-1601 or PA101) is
the only GPR35 activator that has recently been part of clinical
trials,36 there is considerable interest in targeting this receptor.
3.1. Immune Cell Expression and Inflammation. As
highlighted earlier, GPR35 is expressed by human immune
cells including monocytes (CD14+), T-cells (CD3+), neu-
trophils, and various dendritic cells and natural killer T cells
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(CD56+) and has a broadly similar expression pattern in
mouse.1,10,37 More recently, single-cell RNA-seq analysis of
immune cells from the lamina propria and Peyer’s patch cells
from mouse small intestine found GPR35 expression to be
most common in dendritic cells (CD103+CD11b−) and
macrophages clusters, as well as small, 100-cell “unresolved”
clusters.38 Wang et al.1 showed that sustained treatment with
kynurenic acid could inhibit LPS-induced TNF-α secretion
from peripheral blood mononuclear cells. In contrast, however,
Zheng et al.39 have reported that kynurenic acid inhibits LPS
+ATP-induced IL-1β secretion, but not TNF-α secretion, in
mouse bone marrow-derived macrophages and human THP-1
cells. In fact, in these studies the TNF-α level was slightly
increased. It is worth noting that at the 4 h point Zheng et al.39
removed the LPS and kynurenic acid, along with any already
secreted IL-1β or TNF-α, before subsequent stimulation with
ATP. If kynurenic acid inhibited LPS-induced TNF-α
secretion before the wash, then this could have left more
available for secretion after ATP.
On the basis of this expression profile, perhaps unsurpris-
ingly, several SNPs located in the GPR35 gene have been
reported to be associated with immune and inflammation-
related diseases, including inflammatory bowel diseases
(ulcerative colitis and Crohn’s disease), ankylosing spondylitis,
and primary sclerosing cholangitis (Table 2). One of the most
common of these variants, (rs3749171), results in replacement
of a threonine by methionine in transmembrane domain III
(T108M) (Ballesteros and Weinstein position 3.44) and has a
minor allele frequency (MAF) of approximately 0.15 (Table
2). T108 M exhibits strong linkage disequilibrium to several
other variants, at least two of which have been reported to be
associated with disease. These, rs4676410 (r2 = 0.457, D′ =
0.98 LD to T108M) and rs34236350 (r2 = 0.500, D′ = 0.998
LD to T108M), lie outside the coding region; however, they
may increase expression and/or affect the splicing of GPR35 in
certain tissues (GTEx Analysis, release V8). rs4676410 and
rs34236350 are strongly linked to each other (r2 = 0.912, D′ =
0.981) and have similar MAFs (0.27 and 0.26 respectively),
indicating the two are almost always present on the same allele
(Table 3). As noted, T108M is less common but is tightly
linked to both, meaning that almost every allele of T108 M
also contains rs4676410 and rs34236350, making it difficult to
distinguish disease associations between each individual
variant. While in vitro studies showed the T108M variation
to have little effect on potency of agonist ligands,5 Schneditz et
al.40 reported the T108M variation to differentially regulate
baseline Ca2+ levels and Src activation in human induced
pluripotent-stem-cell-derived macrophages, consistent with a
gain of function effect for Met at this position. By contrast, a
further variant, V76M (rs13387859), which did show
reduction in agonist potency5 has not been linked to disease
in GWAS studies, although present at some 2% allele
frequency.
In vivo studies have suggested GPR35 function has a
protective effect on dextran-sulfate sodium (DSS)-induced
colitis.30,41,42 Tsukahara et al.30 demonstrated that treatment
with the GPR35 agonist pamoic acid reduced the severity of
DSS-induced colitis. As such, there appears an opportunity for
GPR35 agonists to be effective in inflammatory bowel diseases.
As noted earlier, various reports have suggested pamoic acid to
have relatively low potency at mouse GPR35 and to function
as a partial agonist;27,43 therefore, it is unclear if agonists of
higher efficacy might be more effective. As discussed earlier the
reported effect of CID2745687 in these studies30 is surprising
Table 2. Single Nucleotide Polymorphisms in GPR35 That Are Associated with Disease
variant loci change MAF disease refs
rs4676410a chr2:240624322 G > A 0.272
ankylosing spondylitis
80−85
eosinophil count
inflammatory bowel disease
primary sclerosing cholangitis
systemic lupus erythematosus
rs34236350b chr2:240628909 C > T 0.261 monocyte count 86
rs3749171c chr2:240630275
C > T
0.151
ankylosing spondylitis
85,87−89
T1083.44 M
psoriasis
inflammatory bowel disease
Crohn’s disease
ulcerative colitis
rs3749172c chr2:240630832
C > A
0.484
Crohn’s disease
79,90,91
S294R coronary artery calcification
rs4676408d chr2:240634984 A > G 0.4
inflammatory bowel disease
92
ulcerative colitis
rs4676406d chr2:240639691 T > G 0.374
ulcerative colitis
87,93
Crohn’s disease
ankylosing spondylitis
psoriasis
primary sclerosing cholangitis
aIntron variant. b5′ UTR variant. cMissense variant. dIntergenic variant. Positions reference Human Genome Assembly GRCh38.p13.
Table 3. Prevalence of Human GPR35 Haplotypesa
aGenerated using LDHap Tool (https://ldlink.nci.nih.gov).
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given its lack of affinity for mouse GPR35 when tested using in
vitro assays. In a related study, GPR35 knockout mice were
shown to have a slightly greater reduction in body weight
compared to wild-type mice in response to DSS treatment, and
this was coupled with earlier and more severe stool and
bleeding symptoms and a larger overall disease score.41
Together, while these studies suggest a protective role for
GPR35 in colitis they seem inconsistent with SNP association
studies linking such lower gut disorders to a gain of GPR35
function and/or expression. However, another study that
examined DSS-induced colitis in social-deficit-stressed mice
found kynurenic acid treatment to result in increased bleeding
and histology scores, while showing no effect on body weight
or colon length.39
This highlights the need for further investigations to better
elucidate the precise role GPR35 plays here and to better
define whether agonist or antagonist treatment might be more
effective. Clearly this may also be a species-related difference,
and indeed, other well-appreciated confounding influences,
including cage effects, were not excluded. As mouse colitis
models are very gender-specific, male and female mice should
both be tested for GPR35 effects. Farooq et al.41 used only
male mice. Given that the endogenous ligand for GPR35 is yet
to be defined, it may also be that observed gains or losses of
function may reflect action of the endogenous ligand(s) at the
receptor.
3.2. Pain and the Nervous System. Several studies have
shown GPR35 expression in sensory-neuron-containing dorsal
root ganglia (DRG), both at transcript29,44−47 and potentially
protein level.44,47 Early studies indicated GPR35 expression in
rat DRG was highest in small- and medium-diameter neurons,
though still present in large neurons,44 while more recent
analysis of isolated mouse DRG cells by single-cell RNA-seq
identified 11 subpopulations of neurons in such DRGs46 in
which expression of GPR35 was predominately in unmyeli-
nated neuron subtypes known to express the voltage-gated
sodium channel Nav1.8, most frequently in the tyrosine
hydroxylase subtype, Th, and three nonpeptidergic subtypes,
NP1−3, along with one myelinated, non-Nav1.8-expressing,
neurofilament subtype, NF1. Analysis of expression of all
GPCRs in Nav1.8-expressing vagal afferent neurons isolated
from mouse nodose ganglia showed high GPR35 expression
and that GPR35 expression was 100-fold lower following
diphtheria toxin ablation of Nav1.8 expressing cells.
48 GPR35 is
also regularly coexpressed with CCK1R and GPR65, two
GPCR-encoding genes known to be associated with gastro-
intestinal afferents.48
We have already commented on the observed pharmacology
of GPR35 in various neurons from rodents to highlight some
inconsistencies in the action of the potential antagonist
CID2745687 (section 2.4). However, co-staining of an anti-
GPR35 antiserum with NeuN, but not GFAP, was consistent
with GPR35 being expressed in neurons in the CA1 region of
rat hippocampus, but not glial cells.49 Of course, a knockout
control for anti-GPR35 specificity is not currently available for
rat; thus, efforts to define specific roles of potentially GPR35
active agonists made use of the blocker ML-145. As
highlighted earlier, this ligand has been employed infrequently
and again, like CID2745687, has been shown unable to block
rat GPR35 in transfected cell studies.26 As there have been
broad concerns over the specificity of many available anti-
GPCR antisera, we recently generated a transgenic knock-in
mouse line in which we introduced the hemeagglutinin (HA)
epitope tag sequence in-frame with the C-terminal tail of
GPR35. This provides exquisite detection of GPR35
expression (Figure 3), in these animals for which wild-type
mouse tissue provides the necessary specificity controls.
Chronic treatment of rats with kynurenic acid has also been
shown to lead to elevated functional CB1 receptor in rat brain,
particularly in the hippocampus.50 However, the broad
spectrum of targets of kynurenic acid, and indeed its
metabolites,51−53 make it all but impossible to attribute such
an effect directly to activation of GPR35.
3.3. GPR35 and Cancer. GPR35 expression has been
linked to various cancers, including gastric, breast, and
colon,1,7,54,55 but its role remains ambiguous, although ligands
such as kynurenic acid can inhibit cell proliferation in such
cancers56−60 and GPR35 expression in breast cancer tissues has
a strong association with advanced histological grades.54
Furthermore, it is reported that colon cancer patients with
lymph nodes expressing high levels of GPR35b have short
disease-free survival times.7 In nonsmall cell lung cancer
(NSCLC), overexpression of GPR35 is associated with poor
prognosis in patients, and GPR35 knockdown significantly
overcomes chemoresistance in NSCLC in vitro and in vivo.55
Such data imply that GPR35 may facilitate cancer growth and
metastasis and, potentially, serve as a clinical tumor marker. It
is, therefore, of considerable interest to investigate the
significance, signaling and function of GPR35 in late stages
of cancers more fully.
Mechanisms of potential relevance to cancer include that
GPR35 can elevate Na/K-ATPase-mediated ion transport to
subsequently activate the epidermal growth factor receptor/
Src/Ras/ERK signaling pathway in colon cancer cells,40 and
Figure 3. Detection of GPR35 expression in the colon of a transgenic
mouse. A knock-in transgenic mouse line was produced in which
mouse GPR35 has in-frame addition of the HA-epitope tag sequence
at the C-terminus of the receptor. Longitudinal (A, B) and cross
sections (C, D) show anti-HA staining throughout the colonic crypts
in the transgenic line (mGPR35-HA) tissue (A, C) compared to wild-
type tissue (B, D) as control. Scale bar = 10 μm.
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Src signaling is a well-known factor that contributes to the
malignancy of many cancers, including colon cancer.61 Indeed,
Schneditz et al.40 further showed that genetic depletion of
GPR35 can reduce intestinal tumorigenesis in both sponta-
neous and inflammation-driven colon cancer mouse models
and that a lipid-coupled peptide (pepducin) able to selectively
inhibit GPR35 activation also reduced tumor burden in a
colitis-associated mouse model. Hypoxia-inducible factor-1α
(HIF-1α) is known to upregulate GPR35 in certain circum-
stances, including in cardiac myocytes during the progression
of cardiac failure,62 and although this feature is not likely of
direct relevance to carcinogenesis, hypoxia is a major feature of
solid tumors that promotes metastasis and supports tumor
recurrence via stimulating cancer stem cell differentiation.63,64
As such, although untested, the efficacy of GPR35 antagonists
in such settings could be of interest.
Although risk factors rather than direct regulators, chronic
inflammation and lipid metabolism are relevant to cancer.
Since GPR35 activation can modulate inflammation and
enhance lipid metabolism, GPR35 agonists could also have
an inhibitory effect on cancer development and progression.
With the caveats discussed earlier around the likely lack of
specificity of many compounds that display low potency
activity at GPR35, molecules such as flavonoid glycosides have
the capacity to act as agonists at GPR35.65 Widespread in
herbs and found to suppress the proliferation of oral and colon
cancer cells,66,67 any effects are more likely akin to
homeopathy, however, rather than reflecting direct GPR35
pharmacology.
3.4. GPR35 and Energy Homeostasis. Energy homeo-
stasis encompasses biological processes regulating food intake,
energy expenditure, and metabolism. Although poorly ex-
plored, some evidence indicates that GPR35 and its ligands
have the potential to regulate this process. As noted earlier,
alongside immune cells, expression of GPR35 is predominant
in organs of the gastrointestinal (GI) tract including stomach,
small intestine, and colon.18 Concentrations of kynurenic acid
are also significant in the GI tract, especially in the small
intestine,68 although as highlighted earlier the potency of
kynurenic acid varies markedly at species orthologues of
GPR35.10,11 The GI tract actively modulates energy balance
through the secretion of peptides hormones, such as
cholecystokinin (CCK) that increases the production of
pancreatic enzymes by relaying signals to the CNS;69 GPR35
is coexpressed with both the CCK1 receptor and the potential
proton sensing receptor GPR65 in GI vagal afferents. This
suggest that GPR35 may be part of the gut−brain signal axis
that regulates energy balance.48
Lipid metabolism is also vital to energy homeostasis. The
major lipid metabolic organs are adipose tissue, liver, and
skeletal muscle. Imbalances of fat storage (adipose tissue) and
free fatty acid oxidation (liver and skeletal muscle) ultimately
results in obesity. It is reported that obese adults have elevated
kynurenine serum levels.70 Although kynurenine is not itself an
activator of GPR35,3,67 it is the precursor of kynurenic acid,
the serum concentrations of which are also raised in leptin-
receptor-deficient Zucker fatty rats, a widely used rat model of
obesity.71 It is thus possible that kynurenine pathway
metabolites, including kynurenic acid, may be associated with
the burden of obesity. A recent study in mice indicated that
kynurenic acid was able to increase lipid metabolism and
thermogenesis in adipose tissue by upregulating expression of
genes associated with lipolysis, fatty acid oxidation, and beige
adipogenesis.72 This increases cellular respiration and energy
expenditure leading to reduction in body weight. As genetic
deletion of GPR35 leads to impaired glucose tolerance and
gain of body weight in mice,72 these effects of kynurenic acid, if
indeed mediated in a GPR35-dependent manner, could control
expression of peroxisome proliferator-activated receptor-γ
coactivator 1α (PGC-1α) in adipocytes. PGC-1α is a
transcriptional coactivator for peroxisome proliferator-acti-
vated receptor (PPAR) family members. PPARs are nuclear
transcription factors and control many physiological processes
such as energy metabolism, inflammation, and cancer develop-
ment73 potentially providing a further link between GPR35
and metabolic function. Key experiments now need to be
undertaken with more carefully selected GPR35-targeted
pharmacological ligands to improve understanding of this
potential link. In addition to the mouse GPR35-HA expressing
transgenic mouse line described above (Figure 3), we have also
recently generated a transgenic knock-in mouse line in which
we replaced mouse GPR35 with an HA-epitope tagged form of
human GPR35a. As this receptor orthologue is blocked by the
antagonist CID2745687, it should now be practical to assess
on-target contributions of GPR35 to metabolic phenotypes in
these animals.
Hepatic steatosis is a common chronic liver disease and can
transform into cirrhosis and hepatocellular carcinoma. It is
defined by an accumulation of lipid in the liver promoted by
energy homeostasis imbalance. The potent human and rat (but
not mouse) GPR35 agonist lodoxamide has been shown to
inhibit lipid accumulation in the human HepG2 cell model
and, rather more surprisingly given the pharmacological
properties of this ligand, mouse primary hepatocytes.74
Lodoxamide was shown to decrease SREBP-1c protein
expression and hence inhibit SREBP-1c-induced lipid syn-
thesis. As such, activation of GPR35 was suggested to offer
therapeutic potential in the control of hepatic steatosis.
However, much remains to be assessed before this could be
actively championed. As noted earlier, GPR35 shows marked
selection for activation of Gα12 and Gα13 over other G proteins
(and indeed for Gα13 over Gα12).
27 Although the impact of
GPR35 on hepatic steatosis remains speculative, Gα12 seems to
play a critical role in hepatic lipid metabolism.75 Activation of
Gα12 had been shown to limit hepatic steatosis by increasing
mitochondrial respiration and fatty acid oxidation in liver.
Knockout of the Gα12 coding gene suppresses sets of genes
related to lipid catabolism, acyl-CoA metabolism, ketogenesis,
and peroxisomal oxidation processes. Notably, PPARα and
PGC-1α are core partners in this gene network. Although at
this stage little more than a hint, these data also provide a
potential link for GPR35 in maintaining energy homeostasis
and preventing the development of hepatic steatosis. GPR35
ligands may thus be worthy of consideration among novel
therapeutic strategies for obesity, glucose intolerance, and fatty
liver disease.
3.5. GPR35 and the Cardiovascular System. Initial
reports of a GPR35 knockout mouse line indicated a
remarkable 37.5 mmHg increase in blood pressure compared
to wild-type littermates,76 which would seem to suggest a
potential opportunity for GPR35 agonists to lower blood
pressure. Sadly, this was not replicated in a subsequent
independent study using a different knockout line.77 Despite
this, a range of studies have noted contributions of GPR35 to
cardiovascular phenotypes (see ref 78 for review). Indeed, an
association between a nonsynonymous GPR35 SNP in the
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intracellular C-terminal tail (rs3749172, S294R) (Table 2) and
coronary artery calcification79 was an early outcome. Despite
being a potential site of agonist-induced phosphorylation,
replacement of this serine residue has not been reported to
result in alterations in function or regulation of the receptor.
Ronkainen et al.62 noted increases in cardiac GPR35
expression induced by hypoxia in mouse models of cardiac
failure and therefore suggested that levels of GPR35 mRNA
might provide an early marker of progressive cardiac failure. As
GPR35 is expressed robustly in human vascular smooth muscle
and endothelial cells, MacCallum et al.32 assessed effects of
GPR35 activation on cell migration and proliferation to assess
the potential that GPR35 ligands might be relevant to
treatment of neointima formation in vein graft failure following
coronary artery bypass treatment. Effects of GPR35 activation
on vascular smooth muscle migration in a scratch-wound assay
were mediated via the RhoA/Rho kinase signaling axis. This is
actively regulated by the Gα12/Gα13 group of G proteins for
which GPR35 actively selects. Overall, however, despite a
number of studies exploring cardiovascular consequences of
GPR35 function, a clear path to functional translation seems
distant.
4. CONCLUDING REMARKS
Despite remaining an orphan GPCR, where suggestions of
various endogenous activators have waxed and waned, GPR35
is attracting increasing interest as a therapeutic target. This is
nevertheless the case in inflammatory bowel disease, based on
both genetic association studies and high level expression in
the colonic tissue and infiltrating white cells. However, the
species-selective nature of the pharmacology of both agonist
and antagonist compounds means that there is an additional
need to fully define ligand effects in the patho-physiological
setting as genuinely being mediated by GPR35 if human tissue
is not available. The suitability of standard rodent preclinical
models to predict function and therapeutic utility for projects
centered on GPR35 are therefore amplified above those
normally considered. Hopefully, the recent development of
humanized and epitope-tagged GPR35 transgenic mouse lines
may help to address these issues.
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